New Zealand - Temporary Supply Disruption to Ultiva injections

GlaxoSmithKline (GSK) has advised of a current disruption to the availability of Ultiva 1mg and 2mg injections due to issues at their manufacturing site. For more information see here. There has been an ongoing issue with remifentanil supply in Australia since early July.
Unless alternative manufacturers can be sourced, remaining supplies of remifentanil should be reserved for cases where its use is clinically necessary and alternatives are inappropriate.
Copyright © Australian and New Zealand College of Anaesthetists.